Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients

We examined the detection of low-level viraemia at week 24 as a predictor of sustained virological response (SVR) and viral relapse/breakthrough, and the agreement between the Roche Cobas TaqMan™ HCV RNA assay (TaqMan) and Roche Cobas(®) Amplicor HCV qualitative assay (Amplicor; both Roche Molecular...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral therapy 2011-01, Vol.16 (2), p.173-180
Main Authors: BALERIOLA, Cristina, RAWLINSON, William D, CHENG, Wendy, RIZKALLA, Bishoy, DUBOIS, Dwight, THOMMES, James, ROBERTS, Stuart, DORE, Gregory, CHAVEROT, Sandra, STELZER-BRAID, Sacha, YOSHIHARA, Motoko, CRAWFORD, Darrell, SIEVERT, William, MCCAUGHAN, Geoffrey, WELTMAN, Martin
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Antiviral Agents - administration & dosage
Antiviral Agents - therapeutic use
Biological and medical sciences
Drug Therapy, Combination
Genotype
Hepacivirus - classification
Hepacivirus - drug effects
Hepacivirus - genetics
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - virology
Human viral diseases
Humans
Infectious diseases
Interferon-alpha - administration & dosage
Interferon-alpha - therapeutic use
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Polyethylene Glycols - administration & dosage
Polyethylene Glycols - therapeutic use
Polymerase Chain Reaction - methods
Reagent Kits, Diagnostic
Recombinant Proteins
Ribavirin - administration & dosage
Ribavirin - therapeutic use
RNA, Viral - blood
Treatment Outcome
Viral diseases
Viral hepatitis
Viral Load
Viremia - drug therapy
Viremia - virology
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We examined the detection of low-level viraemia at week 24 as a predictor of sustained virological response (SVR) and viral relapse/breakthrough, and the agreement between the Roche Cobas TaqMan™ HCV RNA assay (TaqMan) and Roche Cobas(®) Amplicor HCV qualitative assay (Amplicor; both Roche Molecular Diagnostics, Pleasanton, CA, USA) for detection of low-level viraemia. A total of 871 treatment-naive HCV genotype 1 patients participating in an induction-dose pegylated interferon therapy study had virological responses assessed using TaqMan. A total of 151 patients with HCV RNA levels ≤500 IU/ml had samples tested in parallel using the Amplicor and TaqMan assays. SVR was significantly lower and relapse/breakthrough significantly higher in patients with low-level residual viraemia at week 24 compared with those who had undetectable viraemia: SVR was 72%, 29% and 14% (P
ISSN:1359-6535
2040-2058
DOI:10.3851/IMP1731